Tryton’s Innovative Solution Highlighted at Annual European Bifurcation Club Meeting

DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical’s TRYTON Side Branch Stent™ System was discussed as an
important new therapeutic option for patients with bifurcation disease
last week at the annual European Bifurcation Club (EBC) meeting in
Lisbon, Portugal, where approximately 150 international interventional
cardiologists gathered to share best practices for challenging
bifurcation cases.

Patrick W. Serruys, M.D., Ph.D., of Erasmus Medical Center in Rotterdam,
the Netherlands, presented an overview of the Tryton stent system,
highlighting results from a number of studies of the device and the
growing body of clinical evidence supporting the use of the Tryton stent
system.

“In a straw poll conducted at the EBC Meeting two years ago, Tryton was
selected the dedicated stent of choice by a large margin. The
accumulation of clinical data in more than 700 patients, with a rate of
target lesion revascularization consistently less than four percent at
six months, further validates Tryton’s leadership position,” said Prof.
Serruys. “I am particularly excited about the potential of Tryton
technology for the treatment of left main lesions.”

“The EBC represents the finest tradition of collaboration among leaders
within the European interventional community,” said Shawn McCarthy,
president and CEO of Tryton Medical. “Tryton is pleased to work with
these visionaries as we continue a leadership role in pioneering an
innovative solution to this long-standing challenge in interventional
cardiology.”

Coronary artery disease often results in the buildup of plaque at the
site of a bifurcation, where one artery branches from another. Current
approaches to treating these lesions are time consuming and technically
difficult. As a result, the side branch is often left unstented, leaving
it vulnerable to higher rates of restenosis, the re-narrowing of the
stented vessel following implantation. Bifurcation lesions account for
as many as one-third of all coronary lesions.¹ Left main
disease, an accumulation of plaque that narrows the base of the coronary
tree, is a persistent challenge in interventional cardiology, as more
than 75 percent of left main lesions are bifurcation lesions.

About the Tryton Side Branch Stent

The Tryton Side Branch Stent System is designed to offer a dedicated
strategy for treating atherosclerotic lesions in the side branch at the
site of a bifurcation. Tryton’s cobalt chromium stent is deployed in the
side branch artery using a standard single-wire balloon-expandable stent
delivery system. A conventional drug-eluting stent is then placed in the
main vessel.

The stent system has received CE Mark approval in Europe and is
commercially available in 21 countries throughout Europe and the Middle
East. It is approved in the United States for investigational use only.

The randomized, controlled Tryton IDE study will compare the use of the
Tryton stent in the side branch in conjunction with a standard drug
eluting stent in the main vessel vs. the use of angioplasty in the side
branch with a standard drug eluting stent in the main vessel for the
treatment of complex bifurcation disease. The primary endpoint of the
study is target vessel failure at nine months. A secondary endpoint is
percent diameter stenosis at nine months in the side branch vessel as
assessed in an angiographic subgroup.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of
novel stent systems for the treatment of bifurcation lesions. The
company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of
medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical
Center) and Dan Cole to develop stents for the definitive treatment of
bifurcation lesions. The Tryton Side Branch Stent System, approved for
sale in Europe, is designed to offer a dedicated strategy for treating
these challenging cases. Privately held, Tryton is backed by Arnerich
Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest
Ventures. For more information please visit trytonmedical.com.

¹ Scot Garg, et al. EuroIntervention 2011:6: 928-935.
Available online at http://www.pcronline.com/eurointervention/34th_issue/162/